Correlation Between Vascular Endothelial Growth Factor and Long-Term Occurrence of HCV-Related Hepatocellular Carcinoma After Treatment with Direct-Acting Antivirals. (14th September 2021)

• Record Type: Journal Article
• Authors: Ramadan, Haidi K.; Meghezel, El-Zahraa M.; Abdel-Malek, Mohammed O.; Askar, Ashraf A.; Hetta, Helal F.; Mahmoud, Amal A.; Abdel-Aal, Amal M.
• Is Part Of: Cancer investigation. Volume 39:Number 8(2021)
• Page Start: 653
• Page End: 660
• Publication Date: 2021-09-14
• Subjects: VEGF -- HCV -- hepatocellular carcinoma -- angiogenesis -- liver cirrhosis; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2021.1951751
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: We aimed to evaluate the correlation between vascular endothelial growth factor (VEGF) and long-term occurrence of hepatocellular carcinoma after HCV treatment with direct-acting antivirals (DAAs) and the HCC stage. Two groups with HCV-related liver cirrhosis and HCC were included: group 1, HCC following DAAs; group 2, HCC did not receive DAAs. The serum level of VEGF and HCC staging was evaluated. The duration between DAAs and HCC was 21.81 ± 11.66 months. Portal vein thrombosis (PVT) was observed more in group 1 (31%). VEGF was relatively elevated in group 1 compared to group 2. HCC patients after DAAs, showed elevated VEGF with frequent PVT.